Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of five systematic review(s)/meta-analysis(es). ^[1-5]
• Zavegepant 10 mg was effective in achieving pain freedom at 2 hours postdose, with a risk ratio (RR) of 1.54 (95% CI, 1.28 to 1.84) compared to placebo. It also showed superior relief from most bothersome symptoms at 2 hours postdose (RR 1.26, 95% CI 1.13 to 1.42).
• Zavegepant demonstrated a higher likelihood of sustained pain freedom between 2 and 48 hours (OR = 1.74, P < .00001) and reduced pain relapse, though the latter was not statistically significant (OR = 0.67, P = .11).
• Compared to other therapies, Zavegepant was less effective than lasmiditan for pain relief within 2 hours and less effective than rimegepant and ubrogepant for sustaining pain relief over 24 hours, while zolmitriptan 5 mg was the most effective for pain freedom at 2 hours.
• Zavegepant 10 mg was associated with a higher incidence of adverse events compared to placebo, with a risk ratio (RR) of 1.78 (95% CI 1.5 to 2.12). Dysgeusia was the most frequently reported adverse event, occurring significantly more often in the Zavegepant group (RR 4.18, 95% CI 3.05 to 5.72).
• Zavegepant nasal spray demonstrated a lower risk of adverse events compared to other intranasal therapies, with an odds ratio (OR) of 2.04 (95% CI 1.37 to 3.03). Dihydroergotamine nasal spray had the highest risk of adverse events (OR 9.65, 95% CI 4.39 to 21.22).
• There is no population types or subgroups information available in the reviewed documents.